Formycon AG (DE:FYB)
XETRA:FYB
Want to see DE:FYB full AI Analyst Report?
Top Page
Formycon AG
(XETRA:FYB)
Select Model
Select Model
Rating:51Neutral
Price Target:
€19.00
▼(-4.14% Downside)
Action:ReiteratedDate:04/24/26
The score is held back primarily by weak recent financial performance (revenue contraction, significant losses, and deeply negative free cash flow) despite a comparatively strong, low-leverage balance sheet. Technicals are mixed with the stock below key longer-term moving averages and a negative MACD, while valuation is constrained by loss-making results and no indicated dividend yield.
Positive Factors
Balance sheet strength
Low leverage and a well-capitalized balance sheet provide durable financial flexibility for a development-stage biotech. This helps absorb development delays, fund clinical programs, and negotiate partnerships without immediate refinancing pressure, supporting multi-quarter strategic execution.
Negative Factors
Revenue contraction & volatility
Sustained revenue declines and volatility undermine predictable milestone timing and future royalty streams. For a partner-dependent biosimilars developer, weaker top-line trends reduce bargaining power on deals and delay cash receipts tied to approvals and commercial uptake.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Low leverage and a well-capitalized balance sheet provide durable financial flexibility for a development-stage biotech. This helps absorb development delays, fund clinical programs, and negotiate partnerships without immediate refinancing pressure, supporting multi-quarter strategic execution.
Read all positive factors
Formycon AG (FYB) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€332.25M
Dividend YieldN/A
Average Volume (3M)24.96K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth-36.17%
EPS Growth48.61%
CountryDE
Employees250
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.66
Shares Outstanding17,672,928
10 Day Avg. Volume17,772
30 Day Avg. Volume24,962
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.13
Price to Sales (P/S)10.17
P/FCF Ratio-10.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.50Price Target Upside74.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€91.90M
Formycon AG Business Overview & Revenue Model
Company Description
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye disease...
How the Company Makes Money
Formycon primarily makes money through partnering-driven biosimilar development and commercialization arrangements rather than operating a large in-house commercial sales infrastructure. Its key revenue streams generally include: (1) milestone pay...
Formycon AG Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
41
Neutral
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 44.48M | 69.67M | 77.70M | 42.50M | 36.61M |
| Gross Profit | 3.58M | 14.83M | 23.30M | 12.07M | 10.11M |
| EBITDA | -2.44M | -4.10M | 81.05M | 51.53M | -12.42M |
| Net Income | -64.70M | -125.67M | 75.80M | 35.99M | -13.29M |
Balance Sheet | |||||
| Total Assets | 739.53M | 771.72M | 890.36M | 853.70M | 70.72M |
| Cash, Cash Equivalents and Short-Term Investments | 68.85M | 41.84M | 27.04M | 9.82M | 25.18M |
| Total Debt | 9.56M | 10.59M | 29.49M | 49.31M | 5.28M |
| Total Liabilities | 340.39M | 309.87M | 387.61M | 497.12M | 14.82M |
| Stockholders Equity | 399.14M | 461.84M | 502.75M | 356.58M | 55.89M |
Cash Flow | |||||
| Free Cash Flow | -44.11M | -53.16M | -10.88M | -45.75M | -14.48M |
| Operating Cash Flow | 10.78M | -23.22M | -9.85M | -18.99M | -13.54M |
| Investing Cash Flow | -37.45M | -1.46M | -17.38M | -37.07M | -3.93M |
| Financing Cash Flow | 53.68M | 39.48M | 44.44M | 40.85M | 491.00K |
Formycon AG Technical Analysis
Negative
19.82
Price Trends
20.29
Negative
22.24
Negative
23.41
Negative
Market Momentum
-0.32
Negative
55.93
Neutral
81.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FYB, the sentiment is Negative. The current price of 19.82 is above the 20-day moving average (MA) of 18.08, below the 50-day MA of 20.29, and below the 200-day MA of 23.41, indicating a neutral trend. The MACD of -0.32 indicates Negative momentum. The RSI at 55.93 is Neutral, neither overbought nor oversold. The STOCH value of 81.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:FYB.
Formycon AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | €1.42B | -52.01 | 4.98% | 0.13% | ― | ― | |
56 Neutral | €375.95M | -19.51 | 2.97% | ― | 10.39% | 19.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €332.25M | -10.76 | -16.02% | ― | -36.17% | 48.61% | |
51 Neutral | €1.42B | -66.23 | 4.98% | ― | ― | ― | |
47 Neutral | €215.16M | -15.70 | -0.10% | 2.71% | ― | ― |
* Healthcare Sector Average
DE:FYB
Formycon AG
18.80
-5.50
-22.63%
DE:BIO
Biotest
41.00
-1.80
-4.21%
DE:BIO3
Biotest
32.20
2.24
7.48%
DE:SBS
STRATEC Biomedical
17.70
-6.64
-27.29%
DE:ILM1
Medios AG
14.74
2.54
20.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.